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OBJECTIVE — To determine whether daily intake of 1,25-dihydroxyvitamin D3
[1,25(OH)2D3] is safe and improves -cell function in patients with recently diagnosed type 1
diabetes.
RESEARCH DESIGN AND METHODS — Safety was assessed in an open study of 25
patientsaged18–39yearswithrecent-onsettype1diabeteswhoreceived0.25g1,25(OH)2D3
daily for 9 months. An additional 40 patients were randomly assigned to 0.25 g 1,25(OH)2D3
or placebo daily for 9 months and followed for a total of 18 months for safety, -cell function,
insulin requirement, and glycemic control.
RESULTS — Safety assessment showed values in the normal range in nearly all patients,
regardless of whether they received 1,25(OH)2D3 or placebo. No differences in AUC C-peptide,
peak C-peptide, and fasting C-peptide after a mixed-meal tolerance test between the treatment
andplacebogroupswereobservedat9and18monthsafterstudyentry,with40%lossforeach
parameter over the 18-month period. A1C and daily insulin requirement were similar between
treatment and placebo groups throughout the study follow-up period.
CONCLUSIONS — Treatmentwith1,25(OH)2D3atadailydoseof0.25gwassafebutdid
not reduce loss of -cell function.
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T
ype 1 diabetes results from autoim-
munity against the insulin-
producing -cells of the pancreatic
islets (1). A treatment that could stop or
decrease autoimmune destruction of
-cells would provide substantial
progress in type 1 diabetes therapy and
could potentially be effective in prevent-
ing type 1 diabetes in individuals at high
risk of developing the disease (2).
A multinational case-control study
and a birth cohort follow-up study from
Finland with prerecorded exposure data
(3,4) have concluded that vitamin D3
supplementation at birth protects indi-
viduals from type 1 diabetes later in life,
and these conclusions are supported by
meta-analysis (5). Others report lower se-
rumlevelsof1,25-dihydroxyvitaminD3
[1,25(OH)2D3, calcitriol] in patients with
recentlydiagnosedtype1diabetesthanin
healthycontrolsubjects(6),althoughthis
ﬁnding is inconsistent among studies (7).
Mechanistic studies show that
1,25(OH)2D3 modulates dendritic cell
maturation in vitro and in vivo (8–12)
and facilitates a shift from a Th1 to a Th2
immune response (13). Furthermore,
studies in the nonobese diabetic (NOD)
mouse show that 1,25(OH)2D3 reduces
the incidence of insulitis and diabetes
(14). Vitamin D3 has also been shown to
have beneﬁcial effects on insulin action
(15), although a recent large study found
no association between serum vitamin D
concentrationandinsulinsecretionorac-
tion (16).
1,25(OH)2D3 was introduced to the
clinic as a therapy to increase intestinal
calcium resorption and serum levels of
calcium, e.g., in patients with renal insuf-
ﬁciency. For type 1 diabetes, there is one
report of its use in a pilot open study in
which patients received intensive insulin
therapy and either 0.25 g calcitriol on
alternate days or nicotinamide (25 mg/kg
daily) with up to 1-year follow-up (17).
The results of this study were somewhat
inconclusive, showing no difference be-
tween the two arms with respect to -cell
reserve,butamodestandtransientreduc-
tion in insulin requirement in the group
receiving calcitriol at the dose used. To
determine whether 1,25(OH)2D3 could
be used at higher overall doses in patients
with type 1 diabetes and whether this
could reduce -cell loss after type 1 dia-
betes onset, we performed a two-phase
study assessing safety as well as efﬁcacy.
RESEARCH DESIGN AND
METHODS— Patients with recent-
onset type 1 diabetes were referred for
participation in the study from hospitals
or outpatient clinics in Bavaria, Germany,
betweenNovember2000and2006.They
were selected according to the following
criteria: they were 18–39 years of age,
hadbeentreatedwithinsulinforlessthan
2 months (62 days), had a positive result
on testing for islet autoantibodies (anti-
GAD antibodies or anti-IA-2 antibodies),
had plasma levels of calcium, phosphate,
alkaline phosphatase, and creatinine
within the normal ranges, and were com-
pliant with insulin treatment. Exclusion
criteria were disorders in calcium metab-
olism, kidney diseases, malignancy, and
arterial hypertension. Pregnant or lactat-
ingwomenwereexcluded,andfemalepa-
tients with child-bearing potential had to
practiceanacceptablecontraceptivetech-
nique from enrollment until 30 days after
the last dose of study drug. Written in-
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patient. The study was conducted at the
DiabetesResearchInstitute,Munich,Ger-
many, and was approved by the ethics
committee of the Medical Faculty at the
Ludwig-Maximilians University, Munich,
Germany.
The study had two phases. The ﬁrst
was designed to assess safety at the dose
selected for investigation. It was an open
study that included 25 patients (median
ageSD,31.27.3years;14men)who
received treatment with 0.25 g
1,25(OH)2D3 as Rocaltrol (F. Hoff-
mann-La Roche, Basel, Switzerland) daily
at breakfast for 9 months and were fol-
lowed for a total of 18 months (9 addi-
tional months after treatment). Safety
parameters (plasma levels of calcium,
phosphate, alkaline phosphatase, and
creatinine and urinary calcium excre-
tion) were measured at study entry and
at 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, and 18
months. Kidney sonography was per-
formed at study entry and at 9 and 18
months.
The second phase was subsequently
performed to assess the effect of the study
drug on residual -cell function via a
phase II, monocenter, randomized, dou-
ble-blind, placebo-controlled study. For-
ty-one patients were screened, and 40 of
thesewererandomlyassignedtooral0.25
g 1,25(OH)2D3 (n  22; median age 
SD 31.4  6.8 years; 16 men; median
days after diagnosis 35.0) or oral placebo
(n  18; age 24.0  6.0 years; 13 men;
median days after diagnosis 40.0) daily at
breakfast over a 9-month period. Ran-
domization was performed by an inde-
pendent pharmacy (Bastei-Apotheke,
Munich, Germany), and the study medi-
cation was sent coded to the Diabetes Re-
search Institute. Patients returned to the
study center to receive their study drug
supply and have efﬁcacy and safety as-
sessments performed at 0, 1, 2, 3, 4, 6, 7,
9,12,and18monthsforsafety,A1C,and
insulin dose, and at 0, 9, and 18 months
for a mixed-meal tolerance test (MMTT)
and kidney ultrasound.
In both phases of the study, patients
continued their normal insulin regimen
as intensive insulin therapy, unless
changes were clinically indicated. To
avoid possible confounding through dif-
ferences in glycemic control among the
groups, diabetes management and glyce-
mic targets were standardized as much as
possible in all patients. Patients with A1C
levels 8% had additional contacts with
the study investigator to improve their
metabolic control.
Figure 1—Flow of participants. A: Participation in the open study designed to assess safety of 1,25(OH)2D3 (n  25). B: Random assignment into
the phase II, randomized, double-blind, placebo-controlled study to assess efﬁcacy of study drug (n  22 study drug, n  18 placebo).
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Safety parameters included laboratory
tests (plasma calcium, phosphate, creati-
nine, and alkaline phosphatase and uri-
nary calcium excretion in 24 h),
ultrasound of the kidneys at baseline,
month 9 and month 18, and documenta-
tion of adverse events and concomitant
medication. Laboratory tests were per-
formed centrally at the Institute for Clin-
ical Chemistry of the Klinikum
Schwabing using accredited methods.
1,25(OH)2D3 concentration was mea-
sured in an accredited laboratory by ra-
dioimmunoassay (MVZ Prof. Seelig,
Karlsruhe, Germany).
End point assessment during second
phase
Theprimaryefﬁcacyvariablewasthearea
under the curve (AUC0–120 min)C -
peptide (AUC C-peptide) of a MMTT at
18 months. The MMTT (Boost High Pro-
tein from Novartis in an amount of 360
ml) was administered to collect stimu-
lated C-peptide samples (0, 30, 60, 90,
and 120 min) at baseline, at month 9 im-
mediately after the end of treatment, and
at the ﬁnal visit at month 18. Secondary
efﬁcacyvariableswerethepeakC-peptide
after MMTT at 18 months, daily insulin
intake, and glycemic control, assessed by
A1C levels. C-peptide concentrations
were measured in Trasylol-stabilized
EDTA plasma samples using an auto-
mated immunoassay analyzer (AIA 360;
Tosoh,SanFrancisco,CA).Theinterassay
coefﬁcient of variation of the C-peptide
assay is 4.2% at a concentration of 0.71
nmol/l and the lower limit of detection is
0.07 nmol/l. A1C was measured centrally
by high-pressure liquid chromatography.
Antibodies to insulin, GAD65, IA-2, and
ZnT8 were measured by radiobinding as-
say as described previously (18). All mea-
surements were performed with the
operator blinded to group assignment.
Statistical methods
For the analysis of safety, data from the
ﬁrst(safety)andsecond(efﬁcacy)compo-
nent of the study were combined, and all
subjectswhohadatleastonebaselineand
postbaseline measurement of safety pa-
rameters were included. For the analysis
of efﬁcacy, all randomly assigned patients
who had taken at least one dose of study
drug and had some postbaseline data for
the primary efﬁcacy parameter (AUC C-
peptide)wereincluded.Comparisonsbe-
tween groups and between baseline and
follow-up time points were made using
parametrictests(ttest).Withtheassump-
tionthattheAUCC-peptidevalueswould
decrease by 40% over 18 months in the
placebo-treated group, the efﬁcacy phase
of the study had 50% power to detect
50% preservation of AUC C-peptide after
18 months. All hypotheses testing was
two-sided and performed at the 5% sig-
niﬁcance level.
RESULTS
Safety assessments
Forty-one of 47 patients who received
study drug and all 18 patients receiving
placebo completed the 18 months of fol-
low-up (Fig. 1). Plasma and urinary ex-
cretion calcium values did not change
signiﬁcantly during treatment in both
groups (Fig. 2). Plasma calcium and 24-h
urinary calcium excretion values were
above the reference range in 1 and 16.6%
of samples, respectively, from the treat-
ment group and 3.7 and 15.9% of sam-
ples from the placebo group. During the
safety phase, the study drug dose was
temporarily halved in some patients who
had elevated urinary calcium excretion
values, but this had no effect on urinary
calcium excretion. Moreover, these pa-
tients did not have elevated serum cal-
cium. There were no signs of renal
calciﬁcation during the safety phase. All
other safety parameters were within
reference ranges and did not differ be-
tween the treatment and placebo groups
(Table 1). Serum concentrations of
1,25(OH)2D3 increased after 9 months of
treatment (24.6 vs. 30.3 pg/ml; P  0.02;
n  13 patients in the safety recruitment
phase only).
Adverse events reported by at least
10% of patients were upper respiratory
tract infections and rhinitis. The frequen-
ciesofadverseeventsinthe1,25(OH)2D3
treatment group (23 in 10 subjects) and
in the placebo group (13 in 6 subjects)
were comparable. One patient experi-
enced a cholelithiasis with cholestasis,
which was considered to be a serious ad-
verseeventbutnotdrugrelated.Noother
clinically signiﬁcant adverse event was
reported.
Efﬁcacy phase
Of the 40 randomly assigned patients, 38
completed the study and two discontin-
ued for private reasons (Fig. 1). Only
Figure 2—Safety parameters. Plasma calcium concentrations (A) and 24-h urinary calcium excretion values (B) for patients who received study
drug(n47,f)andpatientswhoreceivedplacebo(n18, )over18monthsoffollow-up.DataaremeansSEM.Thereferencecalciumplasma
levels (2.1–2.6 mmol/l) and urine secretion (10 mmol/24 h) are indicated by the dotted line. VitD3,1 ,25-dihydroxyvitamin D3.
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(4.4% treatment and 5.1% placebo). The
treatment and placebo groups were simi-
lar in terms of age, duration of disease,
ethnicity,andbaselineC-peptideconcen-
trations (Table 2). The mean AUC C-
peptideatmonth9and18andthechange
in the mean values from baseline to
month 18 were comparable in the treat-
mentandtheplacebogroups(Table2and
Fig. 3). Both groups had 40% decreases
in mean AUC C-peptide from start of
treatment to end of follow-up at 18
months. Eleven patients maintained
theirAUCC-peptideabovebaselineval-
ues at 9 months (6 treatment and 5 pla-
cebo) and 1 patient (treatment) had an
AUC C-peptide above baseline at 18
months.Similarly,thefastingC-peptide
and the mean peak C-peptide at base-
line and at month 9 and 18 in the treat-
ment and placebo groups were
comparable with 40% decreases over
18 months (Table 2).
The average insulin requirement per
day and per kilogram body weight and
A1C were similar between the treatment
and placebo groups throughout fol-
low-up (Table 2, Fig. 3). The mean A1C
remained 6.5% from month 2 of fol-
low-up in both groups, and the propor-
tion of patients who reached an A1C
6.5% at 18 months was 55% in both
groups.
No differences between treatment
andplacebogroupswereobservedforthe
titer of insulin antibodies, GAD65, IA-2,
and ZnT8 autoantibodies (not shown).
CONCLUSIONS — 1,25(OH)2D3 at
full dose was used for the treatment of
autoimmune diabetes in a trial that in-
cluded adult patients with recent-onset
disease. 1,25(OH)2D3 at a dose of 0.25
g/day proved to be well tolerated. There
were no signiﬁcant safety issues and most
adverse events were considered mild or
moderate and unrelated or unlikely to be
related to the study drug. Treatment with
1,25(OH)2D3,however,providednopro-
tection against the decline of -cell func-
tion after diabetes onset, as measured by
fasting or stimulated C-peptide and did
not improve insulin requirement or met-
abolic control. These data do not support
the use of 1,25(OH)2D3 to improve dia-
betestreatmentinadultpatientswithtype
1 diabetes.
Previous observations in the NOD
mouse showed beneﬁcial effects of
1,25(OH)2D3 in delaying autoimmune
diabetes when the drug was given early
(14)butnotlateduringpre-diabetes(19).
In humans, administration of the less ac-
tive 1--hydroxyvitamin D3 in infancy
was reported to reduce type 1 diabetes
risk (3,4,20). Administration of 1--
hydroxyvitamin D3 was also recently
foundtopartiallypreserve-cellfunction
in patients with latent autoimmune dia-
betes (21). Finally, it was demonstrated
that the beneﬁcial effect of 1,25(OH)2D3
on -cell preservation was similar to that
of nicotinamide when given soon after
onset of type 1 diabetes at a lower dose
thanthatusedinourstudy(17).Ourdata
are in line with those for the NOD mouse
in concluding no beneﬁt when given late
in the disease, i.e., at diabetes onset. Al-
though numbers in the trial were rela-
tively small, there was complete overlap
for the primary and secondary outcome
markers between treatment and placebo
groups. Moreover, both groups were
very similar in their decline in basal,
peak, and AUC C-peptide after a MMTT
as was recently reported for the NBI-
6024 trial of 188 patients with new on-
set diabetes (22).
The dose tested in our study is likely
to be the maximum tolerable dose. The
serum 1,25(OH)2D3 concentration in-
creased after treatment in the open safety
study. Nevertheless, it is possible that the
overall homeostasis of active vitamin D3
concentration in the body was only min-
imally and variably affected. The use of
1,25(OH)2D3 together with other immu-
Table 1—Safety parameters in treatment and placebo groups during study follow-up
Parameter
1,25(OH)2D3 Placebo
Month 0 Month 9 Month 18 Month 0 Month 9 Month 18
n 47 18
Calcium (mmol/l) 2.4  0.1 2.4  0.1 2.4  0.1 2.5  0.1 2.4  0.1 2.4  0.1
Alkaline phosphatase
(IU/ml) 67  19 62  17 60  17 65  26 62  16 63  17
Phosphate (mmol/l) 1.2  0.2 1.2  0.2 1.1  0.2 1.2  0.2 1.2  0.2 1.1  0.2
Creatinine (mg/dl) 0.8  0.1 0.9  0.1 0.8  0.1 0.8  0.1 0.8  0.1 0.8  0.1
24-h calcium
urine excretion
(mmol/24 h) 6.3  3.2 6.0  3.8 6.2  3.3 6.1  3.2 5.5  4.0 5.2  3.1
Data are means  SD.
Table 2—Efﬁcacy parameters in treatment and placebo groups during study follow-up
Outcome marker and time point 1,25(OH)2D3 Placebo P value
n 22 18
AUC C-peptide (nmol/l 	 120 min)
Baseline 90.8  30.3 98.1  33.0 0.47
Month 9 76.3  46.6 77.9  37.7 0.91
Month 18 58.4  47.7 58.0  33.7 0.98
Fasting C-peptide (nmol/l)
Baseline 0.33  0.12 0.34  0.13 0.74
Month 9 0.27  0.21 0.25  0.16 0.77
Month 18 0.19  0.18 0.22  0.15 0.66
Peak C-peptide (nmol/l)
Baseline 1.00  0.37 1.10  0.36 0.36
Month 9 0.79  0.47 0.85  0.39 0.71
Month 18 0.66  0.52 0.63  0.34 0.86
A1C (%)
Baseline 8.4  2.1 8.3  1.6 0.82
Month 9 6.3  0.6 6.0  0.7 0.13
Month 18 6.1  0.6 6.3  0.8 0.51
Daily insulin dose (IU/day)
Baseline 24.9  12.6 24.6  8.9 0.94
Month 9 26.5  13.1 25.8  13.9 0.87
Month 18 35.6  19.2 34.9  18.1 0.92
Data are means  SD.
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diabetes prevention in NOD mice. Our
results do not rule out such combina-
tions, but we suggest that such trials
should show convincing mechanistic ac-
tion in patients such as alteration of den-
dritic cell numbers/function (8–12) or T
cell phenotype (13) before efﬁcacy evalu-
ation. It has also been reported that less
calcemic analogs of 1,25(OH)2D3 could
be used at higher concentrations and that
thesearemoreeffectiveindelayingdiabe-
tes onset in NOD mice (23–25). Thus,
although our ﬁndings do not completely
rule out the use of vitamin D3 for type 1
diabetes treatment after diabetes onset
and need to be supported by mechanistic
studies to determine the immunomodu-
latory effect of treatment in our patients,
they suggest that 1,25(OH)2D3 treatment
in adult type 1 diabetic patients at the
stageofovertdiseasewillhavelimitedpo-
tential for preserving -cell function.
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